NEW YORK STEM CELL FOUNDATION INC

The New York Stem Cell Foundation Inc. specializes in advanced stem cell research and regenerative medicine services, with a focus on induced pluripotent stem cell (iPSC) generation, beta cell differentiation, and patient-derived cellular modeling for disease research. Their technical expertise includes cellular reprogramming, lineage-specific differentiation protocols, and high-throughput cell assay development, particularly for rare genetic disorders such as DiGeorge syndrome. The organization leverages patient-specific iPSC lines to create physiologically relevant in vitro models for functional characterization and therapeutic screening, positioning them as a niche provider of precision cellular biology services for translational research. Their work bridges fundamental stem cell biology with applied biomedical discovery, emphasizing reproducibility, scalability, and clinical relevance in cellular assays. They maintain a consistent relationship with the Department of Health and Human Services and the National Institutes of Health’s NHGRI, delivering specialized stem cell engineering and laboratory testing services aligned with NIH’s mission in genomic and regenerative medicine. Their engagements typically support investigator-initiated research programs requiring bespoke cellular models and functional validation, indicating a trusted partnership in high-complexity, non-clinical biomedical research. The contractor operates primarily under NAICS 541990 for professional scientific services and 541380 for testing laboratory services, reflecting a market position centered on contract research and specialized cell-based assays. Their focus is squarely on the regenerative medicine and precision biology sectors, serving government-funded research initiatives that demand technical rigor in cellular manipulation and characterization. As an 8H entity based in New York, NY, the organization is structured as a small business without federal certifications. Its geographic footprint is localized but strategically aligned with the biotech and academic research ecosystem of the Northeast corridor, enabling close collaboration with NIH-funded institutions and academic medical centers.